Breaking News
December 14, 2018 - Blood test helps identify distinct molecular signatures in children with cystic fibrosis
December 14, 2018 - Scientists use water to track electrical activity of nerve cells
December 14, 2018 - Recurrence of urinary tract infection may depend on bacterial strain, study shows
December 14, 2018 - GBT Announces U.S. FDA Agrees with its Proposal Relating to Accelerated Approval Pathway for Voxelotor for the Treatment of Sickle Cell Disease and GBT Plans to Submit New Drug Application (NDA)
December 14, 2018 - Partial Thromboplastin Time (PTT) Test: MedlinePlus Lab Test Information
December 14, 2018 - Common tactics for health promotion at work may be detrimental to employees with obesity
December 14, 2018 - Myths about migration and health not supported by available evidence
December 14, 2018 - Recent findings on rare genetic disorder may help develop new treatment options
December 14, 2018 - New drug shows promise in treating sarcomas
December 14, 2018 - Scientists perform lung lavage as new approach for tuberculosis diagnosis in rhinoceros
December 14, 2018 - Recent winners of the Nobel Medicine Prize
December 14, 2018 - KHN’s ‘What the Health?’ Insurance enrollment is lagging — and there are lots of reasons why
December 14, 2018 - Study assesses safety and efficacy of new treatment for pancreatic cancer
December 14, 2018 - Study finds drug targets for Ebola, Dengue, and Zika viruses
December 14, 2018 - Study highlights need for personalized approach to treat ICU acquired delirium
December 14, 2018 - Massage helps relieve pain, improve mobility in patients with knee osteoarthritis
December 14, 2018 - Researchers explore home healthcare nurses’ knowledge attitudes toward infection control
December 14, 2018 - Average outpatient visit in the U.S. costs nearly $500, shows new study
December 14, 2018 - Reference Infliximab, Biosimilar Equivalent for Crohn’s Disease
December 14, 2018 - New contact lens to treat eye injuries
December 14, 2018 - Acne could have a genetic basis find researchers promising new cure
December 14, 2018 - Higher physical activity associated with improved mood
December 14, 2018 - New UGA study points to optimal hypertension treatment for stroke patients
December 14, 2018 - Study highlights factors that can reduce food cravings
December 14, 2018 - Researchers discover Ebola-fighting protein in human cells
December 14, 2018 - Fentanyl surpasses heroin in cause of U.S. drug overdose deaths
December 14, 2018 - When Heart Attack Strikes, Women Often Hesitate to Call for Help
December 14, 2018 - A warning about costume contacts
December 14, 2018 - Study examines link between peripheral artery disease and heart attack
December 14, 2018 - Researchers develop biotechnological tool to produce antifungal proteins in plants
December 14, 2018 - 3D-printed adaptive aids can benefit patients with arthritis
December 14, 2018 - Chronic bullying during adolescence impacts mental health
December 14, 2018 - Integral Molecular and Merus collaborate to develop bispecific antibody therapeutics
December 13, 2018 - Importance of cell cycle and cellular senescence in the placenta discovered
December 13, 2018 - Gold “nanoprisms” open new window into vessels and single cells
December 13, 2018 - Research findings could lead to new targets for cancer-fighting therapeutics
December 13, 2018 - Butantan Institute signs collaboration agreement with MSD to develop dengue vaccines
December 13, 2018 - Study explores how patients want to discuss symptoms with doctors
December 13, 2018 - RUDN medics first to gather scattered data on hepatitis morbidity in Somalia
December 13, 2018 - Age and gender disparities found in use of bed nets to prevent malaria in sub-Saharan Africa
December 13, 2018 - Caffeine therapy benefits developing brains of premature babies
December 13, 2018 - New review focuses on electrospinning techniques used in musculoskeletal tissue engineering
December 13, 2018 - A new division focused on human immune system
December 13, 2018 - Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of Fintepla (ZX008) in Dravet Syndrome
December 13, 2018 - BCR ABL Genetic Test: MedlinePlus Lab Test Information
December 13, 2018 - Caffeinated beverages during pregnancy linked to lower birth weight babies
December 13, 2018 - Stanford Medicine Health Trends Report examines opportunity to democratize health care
December 13, 2018 - Obsessive-compulsive disorder may protect individuals from obesity
December 13, 2018 - Scientists investigate how a painful event is processed in the brain
December 13, 2018 - Genetic study reveals new insights into underlying causes of moderate-to-severe asthma
December 13, 2018 - Study uncovers new genetic clues to frontotemporal dementia
December 13, 2018 - Vitamin C supplementation for pregnant smokers may reduce harm to infants’ lungs
December 13, 2018 - New study reveals yin-yang personality of dopamine
December 13, 2018 - Research identifies nerve-signaling pathway behind sustained pain after injury
December 13, 2018 - Children with high levels of callous traits show widespread differences in brain structure
December 13, 2018 - Long-term Benefit of Steroid Injections for Knee Osteoarthritis Challenged
December 13, 2018 - Adding new channels to the brain remote control
December 13, 2018 - In the Spotlight: A different side of neuroscience
December 13, 2018 - Medical Marvels: Using immunotherapy for melanoma that spread to the brain
December 13, 2018 - Puzzles do not keep dementia away finds study
December 13, 2018 - New mouse model shows potential for rapid identification of promising muscular dystrophy therapies
December 13, 2018 - Study reveals urban and rural differences in prenatal exposure to essential and toxic elements
December 13, 2018 - New collaborative partnership in quest of novel antibiotics
December 13, 2018 - Single tau molecule holds clues to help diagnose neurodegeneration in its earliest stages
December 13, 2018 - AHA Scientific Statement: Low Risk of Side Effects for Statins
December 13, 2018 - What Is Acute Flaccid Myelitis?
December 13, 2018 - How bereaved people control their thoughts without knowing it
December 13, 2018 - Health care democratization underway, according to 2nd annual Stanford Medicine Health Trends Report | News Center
December 13, 2018 - Going Beyond a Single Color
December 13, 2018 - London-based startup launches ‘thedrug.store’ aiming to clean up CBD industry
December 13, 2018 - Loss of tight junction barrier protein results in gastric cancer development
December 13, 2018 - Novel way to efficiently deliver anti-parasitic medicines
December 13, 2018 - RKI publishes new data on disease prevention and utilization of medical services
December 13, 2018 - High-tech, flexible patches sewn into clothes could help to stay warm
December 13, 2018 - The CCA releases three reports on requests for medical assistance in dying
December 13, 2018 - Restoring Hair Growth on Scarred Skin? Mouse Study Could Show the Way
December 13, 2018 - Probiotic use may reduce antibiotic prescriptions, researchers say
December 13, 2018 - Drug repositioning strategy identifies potential new treatments for epilepsy
December 13, 2018 - Chronic rhinitis associated with hospital readmissions for asthma and COPD patients
December 13, 2018 - Food poisoning discovery could save lives
A Little Dab’ll Do Ya to Prevent Squamous Cell Carcinoma

A Little Dab’ll Do Ya to Prevent Squamous Cell Carcinoma

image_pdfDownload PDFimage_print

Action Points

  • Topical fluorouracil (5%, applied twice daily to the face and ears for up to four weeks) reduced the risk of squamous cell carcinoma (SCC) requiring surgery by 75% in the first year after use, in a randomized trial of 932 veterans at high risk for keratinocyte carcinoma (SCC and basal cell carcinoma).
  • Note that risk of BCC was similar in the first year in the fluorouracil group and in controls, and there was no difference in risk of either SCC or BCC over the full four-year trial period.

A randomized trial of 932 veterans at high risk for keratinocyte carcinoma showed that topical fluorouracil, 5%, applied twice daily to the face and ears for up to four weeks, reduced the risk of squamous cell carcinoma (SCC) requiring surgery by 75% in the first year after use (risk ratio 0.25, P=0.002), researchers found.

Risk of basal cell carcinoma (BCC), however, was similar at about 10% in the first year in the fluorouracil group and in controls, reported Martin A. Weinstock, MD, PhD, of Providence Veterans Affairs Medical Center in Rhode Island, and colleagues online in JAMA Dermatology.

There was no difference in risk of keratinocyte carcinoma in year 1 and the risk of either SCC or BCC was not reduced over the full four-year trial period. Moreover, patients reported a high rate of severe or moderate adverse effects during treatment.

Nevertheless, most participants said they would repeat the treatment if it was shown to be conclusively effective in preventing skin cancer. These findings suggest a possible role for the annual use of topical fluorouracil chemoprevention in special high-risk populations, including patients who have received transplants, the investigators said.

In the United States, keratinocyte carcinoma accounts for about three-quarters of all cancers, and incidence is rising.

“It is reasonable at this point to consider the use of a standard and perhaps annual course of topical fluorouracil, 5%, to the face and ears for the reduction of SCC risk in high-risk populations, and potentially for a reduction in need for Mohs surgery,” Weinstock and colleagues wrote. “Topical fluorouracil is the first agent we know of that demonstrates extended post-treatment effects in SCC chemoprevention.”

No “rebound” effect of increased SCCs was observed in the fluorouracil group in year 2 or subsequently. However, the investigators did note a large 49% reduction in the number of fluorouracil group participants who had Mohs surgery treatments for BCCs and keratinocyte carcinoma compared to controls.

More study is also required to better define the effect of fluorouracil on BCC risk, including BCC that requires Mohs surgery, they said.

For the the Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial, participants were recruited from May 2009 through September 2011, and followed through June 2013. Almost all were male (98%) with a median age of 70 years.

Treatment and control groups were matched for demographic characteristics, military service periods, sunburn, Fitzpatrick skin type, sun protection use during the study, and medical histories, including at least two prior BCCs or SCCs.

In addition to the fluorouracil treatment, participants also received a 30 SPF sunscreen and received education about skin cancer, sunscreen, and sun safety.

Median follow-up was 2.8 years and 97% of participants in each group were followed for at least one year after randomization.

In the first year, 95 of 299 participants (32%) developed BCC and 25 of 108 participants (23%) developed SCC including five participants (1%) in the fluorouracil group and 20 (4%) in the control group.

The only difference in BCC risk was seen in year 2 of the study, the study authors report. Notably, this risk was higher in the fluorouracil group (87 versus 59 tumors; P=0.01).

There were no differences in BCC risk in years 1, 3, or 4 and the only difference in SCC risk was the significant decrease seen in year 1.

Among 27 participants in the control group, 36 underwent Mohs treatment for BCCs and 14 participants in the fluorouracil group underwent Mohs for 17 BCCs (RR 0.51, P=0.045). Five patients in the control group and three in the fluorouracil group were treated for SCCs requiring Mohs surgery.

In year 1, the RR for keratinocyte carcinoma was 0.51 (P=0.02) and there were no differences between groups over the 4-year study period.

Weinstock and colleagues acknowledged the adverse effects of fluorouracil and consequently evaluated participants’ completion of the medication course, the occurrence of adverse events, and patients’ attitudes toward using the drug in the future.

A total of 85% of fluorouracil participants (397 of 468) and 96% of controls completed at least 28 doses of the study medication. However, only 31% of those taking fluorouracil group completed 56 doses compared to 81% of controls.

After 2 weeks, 92% of participants in the fluorouracil group reported erythema, and 61% had mild-to-moderate crusting.

After six months, 21% in the fluorouracil group retrospectively rated treatment adverse effects as “severe,” 40% as “moderate,” 25% as “mild,” and 14% as “none.” At the six-month check-in, 76% of controls reported no adverse effects.

When surveyed at six and 12 months, 87% of fluorouracil group participants said they would repeat treatment if it was shown to be effective in reducing future skin cancers.

“This trial demonstrates a proactive approach that is effective,” the study authors point out. Although annual application may be needed since the effect appears to last for only a year, clinical experience indicates there may be fewer adverse effects with the second and third application, they noted. This may be due to improvement in keratinocytic dysplasia following application to sun-damaged areas.

More study is needed to more precisely define the groups that would most benefit, they added.

A randomized study has shown that daily ingestion of a large dose of nicotinamide (NNA) can reduce the risk of SCC and BCC by 23%. However, this beneficial effect disappears as soon as dosing stops, Weinstock and colleagues said. Notably, the results indicated that nicotinamide may simultaneously increase the risk of the most aggressive types of BCC and SCC.

Study limitations include the potential unblinding of participants (but not investigators) due to the adverse effects of treatment as well as potential limited generalizability to women and younger individuals.

This study was supported by the U.S. Department of Veterans Affairs. Lead study author Weinstock reported relationships with AbbVie, Castle, and Celgene. One co-author reported a relationship with Pfizer. Other study authors declared they had no potential conflicts of interest.

2018-01-04T16:30:00-0500

Tagged with:

About author

Related Articles